Arcturus Therapeutics Holdings Inc.
ARCT
$8.25
-$0.39-4.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -92.99% | -68.39% | -58.84% | -43.24% | -22.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.99% | -68.39% | -58.84% | -43.24% | -22.70% |
| Cost of Revenue | -38.31% | -44.09% | -40.55% | -49.58% | -34.87% |
| Gross Profit | -253.22% | 17.77% | -340.80% | 85.49% | 64.58% |
| SG&A Expenses | -16.35% | 13.30% | -21.68% | -16.06% | -23.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.93% | -31.44% | -35.77% | -43.77% | -32.47% |
| Operating Income | -71.94% | 6.25% | -53.79% | 45.02% | 44.67% |
| Income Before Tax | -91.56% | 3.09% | -88.88% | 47.16% | 46.78% |
| Income Tax Expenses | -- | 0.00% | -- | 102.67% | -- |
| Earnings from Continuing Operations | -91.56% | 3.09% | -94.81% | 46.68% | 47.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.56% | 3.09% | -94.81% | 46.68% | 47.51% |
| EBIT | -71.94% | 6.25% | -53.79% | 45.02% | 44.67% |
| EBITDA | -76.43% | 5.99% | -60.30% | 46.40% | 45.69% |
| EPS Basic | -82.69% | 6.92% | -93.88% | 46.99% | 47.95% |
| Normalized Basic EPS | -82.74% | 6.92% | -88.02% | 47.48% | 47.24% |
| EPS Diluted | -82.69% | 6.92% | -93.88% | 46.99% | 47.95% |
| Normalized Diluted EPS | -82.74% | 6.92% | -88.02% | 47.48% | 47.24% |
| Average Basic Shares Outstanding | 4.85% | 4.12% | 0.47% | 0.60% | 0.85% |
| Average Diluted Shares Outstanding | 4.85% | 4.12% | 0.47% | 0.60% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |